US FDA approves Mesoblast's cell therapy for graft-versus-host disease

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast (NASDAQ:MESO )'s cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease.

Source: Investing.com